Drug manufacturers may be held liable for a “false marking” claim under a federal whistleblower law for printing expired patent numbers on their product packages even when they have fully complied with the Hatch-Waxman Act by submitting accurate patent expiration dates for publication by the FDA, a federal judge has ruled.

Senior U.S. District Judge Ronald L. Buckwalter had previously dismissed all claims in Hollander v. Ortho-McNeil-Janssen Pharmaceuticals Inc . on the grounds that the plaintiff had failed to allege with specificity that the drug manufacturer had acted with an “intent to deceive the public.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]